have obtained higher returns than in earlier periods. In addition, it is instructive to examine how returns are affected by the drug pricing patterns which emerged in the 1980s. Real price increases in pharmaceuticals have received increasing attention by policymakers, including recent congressional hearings (U.S. Congress 1985 Congress , 1987 ). Another important objective is to analyze the effects of several policy developments, such as evolving cost containment programs. Insights into the potential impact of these changes on R&D returns can be obtained from a sensitivity analysis of our main results.
The next section of the paper discusses prior studies and recent trends in the pharmaceutical industry in more detail. The following one covers the major assumptions and basic methodology of the analysis. The final two sections present the main findings and the results of various sensitivity analyses. A major limitation of all the current studies is that they employ data and extrapolate drug industry trends from the 1960s and 1970s. None employ any data from the 1980s.2 However the investment and product life cycles for new pharmaceuticals span several decades of time. Moreover, the industry has experienced important changes in recent years that have potentially significant implications for the returns to R&D.
Prior Studies and Recent
First, there appears to be a distinct improvement in research opportunities within the last decade.3 There has been an explosive growth in basic biomedical knowledge and research. Consistent with this situation, pharmaceutical R&D is increasingly characterized by a "discovery by design" approach. This in contrast to the random screening approach which was more prevalent in the earlier post World War II period (Grabowski and Vernon 1983, Chapter 2). In addition, research is now increasingly directed to chronic rather than acute health care problems. Drug therapies for chronic use have accounted for an increasing share of the major new drug introductions of recent periods.
There have also been important changes in the life cycle pattern of expected revenues for new product introductions during the 1980s. There is some evidence that product lifetimes are becoming shorter. A more rapid introduction of close substitutes to the pioneer drug compound in various therapeutic groupings is taking place.4 This apparently 2 The most recent study by Joglekar and Patterson (1986) examines 218 new chemical entities introduced between 1962 and 1977. The latest year for which sales data were utilized was 1981 in this study. Their sensitivity analysis considers some of the emerging trends in the 1980s, such as increased generic competition and changing drug price behavior. This is also suggested by a recent analysis of the new products achieving 100 million dollars of U.S. sales by the fifth year of market life. There were 11 such products introduced between 1977 and 1982 as opposed to only 3 such products introduced between 1970 and 1976 (Grabowski 1989). 4 A good example of this phenomenon is the case of Tagamet, the leading product introduction in terms of U.S. sales in the 1970s. Since its introduction in 1978, there have been three anti-ulcer product substitutes introduced and one of these products, Zantac, now has a larger share of the market. A regression analysis that we performed on the sales of new product introductions in our sample indicates that peak sales are generally occurring sooner after the date of introduction than was the case for older products. reflects several factors. These include increased diversification of R&D programs by major firms and the ability of firms to use the discovery by design approach to produce closely substitutive as well as pioneer products.
The most significant change in product life cycles, however, is the much greater generic competition experienced in the post-patent period. Traditionally in pharmaceuticals, when the patent of a pioneering brand expired, the loss of sales to less expensive generic products occurred only very gradually (Statman 1981 ). However, this situation has changed dramatically in the 1980's. The repeal of state anti-substitution laws and the passage of the 1984 Drug Price Competition and Patent Restoration Act have been important factors in this regard.5 In preliminary research covering 18 drug compounds in which a patented brand name product was first subjected to generic competition in the 1983-1987 period, we have found that generics achieved an average unit market share of 49 percent by two years after market entry (Grabowski and Vernon 1989).
There has also been an important change in industry pricing behavior. During the 1970s, U.S. drug prices lagged overall economy wide inflation. At the end of the 1970s, however, drug firms began increasing product prices significantly faster than inflation. This pattern has persisted throughout the 1980s. This has important implications for drug profit margins, as discussed below.
Another significant change during the 1980s relates to sales of U.S. introductions in foreign markets. Throughout the previous decade, an upward trend was observable in the ratio of foreign to domestic sales for U.S. drug firms. However, during the 1980s, foreign sales have not increased relative to U.S. drug sales. This reflects the oscillating movements in exchange rates as well as the moderating growth rates of pharmaceuticals in foreign markets.
In sum, there have been major structural changes in recent years influencing both the inputs and outputs from pharmaceutical R&D. Hence studies of the returns to R&D which simply extrapolate the trends of the 1960s and 1970s to future periods are likely to have significant limitations.6 A re-examination of the returns to R&D utilizing more recent industry experiences and data would therefore appear appropriate.
Data Samples and Methodology

A. Overview
As discussed, the first objective is to measure the historical performance of New Chemical Entities (NCEs) introduced during the 1970s. The basic sample is 100 NCEs approved by the FDA and introduced into the United States between 1970 and 1979.7 For each NCE, annual cash flows are estimated over the compound's projected product life. A key question analyzed is whether the present value of cash flows from the average NCE covers average R&D investment costs, including the opportunity cost of capital. This 5 The Drug Price Competition and Patent Restoration Act allows easier approval of generic products by the FDA and also results in longer effective patent lifetimes for new drug introductions. However, the primary short-run effect of the Act is to facilitate generic competition for drugs now coming off patents. A preliminary analysis of these developments and the economic impacts of the Act is presented in Grabowski and Vernon (1986). 6 In this regard, Joglekar and Patterson ( 1986) assume in their base case analysis that the ratio of worldwide sales to U.S. sales would increase steadily and that drug prices would lag overall inflation during the rest of the century, based on an extrapolation of trends observed in the 1 960s and 1 970s. If one modifies these assumptions to take account of the 1980s experience in pharmaceuticals, rates of returns are influenced in both a positive and negative manner. 7Our sample excludes new drugs in the cancer area because they are typically developed jointly with the National Institutes of Health. Similarly drugs discovered and developed by nonprofit institutions and universities are excluded because the R&D costs of these compounds would not be representative of drugs emanating from the pharmaceutical industry.
analysis is performed on a real after-tax basis. Both cash flows and R&D expenditures are expressed in constant 1986 after-tax dollars, utilizing a tax rate appropriate to the pharmaceutical industry.
The analysis is performed from the perspective of a long-run capital investment decision. Hence, cash flows are compared to fully allocated R&D investment expenditures. The latter include discovery costs common to all NCEs and the costs associated with R&D failures. It is, of course, rational for firms to continue to make incremental investments as long as cash inflows are expected to cover all future cash outflows on a net present value basis. Over the long run, however, a firm's total portfolio of new drug introductions must cover all investment costs, including "dry holes" and opportunity costs, if R&D is to remain a viable enterprise. In this regard, it is therefore instructive to ask whether the full portfolio of drugs emanating from the pharmaceutical industry over a period of several years covers the industry's opportunity cost of capital. This is a principal issue to be considered in the first half of the paper.
B. Opportunity Cost of Capital
The cost of capital for pharmaceuticals in this study is based on an analysis of the capital asset pricing model (CAPM) estimated at various points in time between mid70s and mid 80s.8 An analysis of investment riskiness was first undertaken for a representative portfolio of pharmaceutical firms. This indicated that pharmaceutical firms had comparable riskiness to the market over this period (i.e., betas approximately equal to one). Long-term estimates on the risk free rates and the market equity risk premia were then obtained using the analysis of Ibbotson (1987) . Using these inputs to the CAPM, the estimated cost of equity capital for pharmaceuticals exhibited a central tendency around 9 percent for the time period studied.9 This value is utilized therefore to capitalize R&D costs and all cash flows in the present analysis.10
C. R&D Costs
The most comprehensive analyses of R&D expenditures in pharmaceuticals was performed by Ron Hansen (1979 Hansen ( , 1980 . He utilized cost data from a significant sample of 8 Since the capital structure of pharmaceuticals is overwhelmingly equity financed (in excess of 90 percent), the cost of equity capital provides a good proxy for the overall cost of capital. This issue has been examined in Statman ( 1983) . Joglekar and Patterson ( 1986) compare R&D returns in pharmaceuticals with the returns on corporate bonds. As the authors recognize, this is a very conservative approach, in that the returns on corporate bonds have been significantly below that for equities over the relevant time period. 9 The return on long-term government bonds rather than the return on short-term bills was used to compute the risk free rate (and the market equity risk premia) since we are dealing here with long term investment projects The values for intervening years also cluster around 9 percent.
10 An alternate approach to estimating the cost of capital would be to utilize the "hurdle rates" derived from surveys of U.S. industrial firms. The results of these two approaches yield very similar values for average R&D costs over the 1970s. In particular they indicate the average R&D costs for 1970-79 introductions, capitalized at 9 percent and expressed in 1986 dollars is in the neighborhood of 125 million dollars.15 By way of comparison, Hansen's original average R&D cost estimate, capitalized at 9 percent and updated for inflation, would be equal to 100 million dollars in 1986 dollars. The difference between these values provide a measure of the net increase in real R&D costs during the 1970s. A recent study by Wiggins (1987) also finds that R&D costs have increased significantly in real terms over time. 16 We also found that there is a considerable variance around our mean R&D cost estimate. In particular, the year to year fluctuations can be 20 percent above or below the average. Recognizing this, we examine a range around the baseline value in the sensitivity analysis. In addition, NCE introductions in the latter half of the 1970s have significantly higher mean R&D costs than those introduced in the first half of the 1970s. This is relevant when we examine particular time cohorts in our analysis of R&D performance.
D. Domestic Sales Revenues and Product Life Cycles
We next turn to the issue of estimating cash flows for our sample of NCE introductions. The first step in this estimation process was to assemble data on the U.S. By contrast, the drug compound in Figure 1 -B is a more recent introduction. It has many fewer years of actual sales data available (9 years). This drug is in the peak sales portion of its product life cycle. Using our representative life cycle curve, this product is projected to have relatively stable sales until year 12. This is the year when its patent expires and generic entry occurs. A significant decline in sales is projected after that point due to both generic competition and product obsolescence.
Our procedures produce a representative life cycle sales pattern for each new drug introduction that is related to its specific patent date and other economic factors. The amount of error introduced into our present value analysis from the extropolated sales values should be minimal. This is because we have actual sales data for most compounds through their period of peak sales. Furthermore, the later segments of the product life cycle are not only subject to intensive generic competition, but are also heavily discounted in present value terms. Figure 2 shows the life cycle sales estimates for the mean, median and the top few deciles of our sample. This figure illustrates the highly skewed distribution of sales which exists for new product introductions in pharmaceuticals. In particular, the peak sales of the top decile are several times that of the next ranked decile of drugs. In addition the mean values are much higher than the median. This high degree of skewness has important implications for the returns to pharmaceutical R&D.
E. Worldwide Sales Revenues
To obtain estimates of worldwide dollar sales, we utilize a foreign sales "multiplier." In an earlier paper, we examined domestic and worldwide sales for a representative These diffierent data sources indicate that the ratio of worldwide to U.S. sales has fluctuated between 1.75 to just over 2.0 for the decade of the 1970s and 1980s. This would also appear to be a relevant range for the immediate future using U.S. Treasury Department's exchange rate projections. Accordingly, a representative value of 1.9 is utilized for the worldwide sales multiplier in our baseline analysis. The broader range of observed values is examined in the sensitivity analysis.
F. Pricing Trends and Pre-tax Contribution Margins
To obtain cash flows from sales, sales are multiplied by the pre-tax "contribution" margin (i.e., pre-tax profits plus R&D costs as a percent of sales). Past studies of the retur ns to R&D have used contribution margins between 25 and 45 percent. The contribution margin also has been typically assumed to be constant over time, despite the fact that chang'e in real drug prices will cause margins to fluctuate in a corresponding fashion.
In this study, margins are derived using income statement data from the pharmaceutical business divisions of twelve major health oriented firms. Using this information (and data on R&D to sales ratios from industry trade sources), we estimated average drug industry contribution margins over the period 1973-1986. 18 These values are plotted in 18 Ideally, one would have data on margins on new product introductions rather than data for all pharmaceutical products. It is not clear what biases this introduces into the analysis. Reekie ( 1979) has found that products with significant therapeutic advantages over existing products will command a price premium. At the same time, he found many products are launched at discounts compared to market leaders. In addition, recent work suggests that older drugs experiencing generic competition do not typically lower prices to match those of their cheaper rivals. Rather, they usually increase prices while their unit sales erode (Grabowski and Vernon 1989). Since these post-patent drug products have much lower distribution and administrative costs, they could have higher margins than a representative grouping of newer products. 
G. Tax Rates
An analysis of historical data since 1970 indicates that the average effective tax rate for most drug firms has been in the range of 30 to 45 percent. This is below the statutory rate and reflects various credits available in federal laws which lower average effective rates.2" The recently enacted Federal tax reform reduces the federal statutory rate for corporations in future periods, but also curtails the ability of firms to utilize particular credits to lower effective tax rates. It is not clear at this point whether effective tax rates will change significantly.
Based on our empirical analysis, a 35 percent tax rate is utilized as a representative baseline tax rate for the pharmaceutical industry for the period of study. This rate was also employed by Joglekar and Patterson ( 1986) in their recent study. Since both R&D inputs and cash flow revenues are affected in a roughly proportional manner by the tax rate, our present value analysis should not be highly sensitive to the tax rate parameter utilized. This issue is examined in the sensitivity analysis.
H. Outlays for Product Launch, Fixed Capital and Working Capital
Pharmaceutical products typically experience heavy promotional expenditures in the first few years of product launch. In the current analysis we assume promotional expenditures equal to sales in year one, declining to 50 percent and then 25 percent of sales respectively in year two and three after product launch. This is based on a separate analysis of drug promotion expenditures for new products using audit data from IMS. These upfront promotional expenditures result in realized pre-tax margins below the assumed steady state values in the first few years of market life, in accordance with general industry experience.
In our analysis, total plant and equipment expenditures are assumed to be equal to 50 percent of tenth year sales for each new product introduction.22 This ratio was based on balance sheet data of firms with a high degree of specialization in pharmaceuticals. For working capital, it is assumed that accounts receivable represent 1.3 months of annual sales and inventories are 5 months of sales (valued at the product's manufacturing cost). All working capital is recovered in the final year of product life.
After-tax cash flows are also affected by differences in book and tax depreciation methods. Book depreciation is based on a straight line accounting method, while tax depreciation is based on an accelerated schedule in accordance with the U.S. tax code. The more rapid depreciation for tax purposes results in positive cash flow in earlier years in the form of deferred taxes, which then reverses in later years.
Results
A. Average Investment Returns
Using the above data and assumptions, we first examine the performance of the mean NCE introduction during the 1 970s. The results are presented in Table 1 . A major finding is that the present value of cash flows and R&D investment are approximately the same 21 Both the investment tax credit (repealed by the 1986 Tax Reform Act) and research and development tax credit (reduced by this Act) are reflected directly in the average effective tax rate of the pharmaceutical industry. A more refined analysis would investigate the effects of these factors separately rather than combining them in a net effective tax parameter. However, as shown below, the results are not highly sensitive to tax rates. 22 Approximately two-thirds of the required capital expenditures are allocated in the two years prior to product launch. The remaining outlays are allocated between year two and ten of product life and are used for maintenance and replacement capital. While the observed positive change in performance between the first and second half of the 1970s may be the result of normal statistical fluctuations, it is also consistent with 23 We also examined the internal rate of return for these two subperiods. This analysis is subject to the qualification that there is uncertainty about the time pattern of R&D costs applicable to these sample periods. However, if one essentially utilizes a time pattern for R&D identical to Hansen's (with proprotional adjustments in annual costs), the internal rate of return is equal to 7.1 percent for the 1970-74 period, while it is 10 percent for the 1975-79 period. Table 1 by 14 percent. These computations illustrate the 24 We investigated the issue of whether R&D costs were positively related to a compound's decile class. We found there was a slight positive (but statistically insignificant) relationship between a compound's decile class and its R&D costs. However, our analysis was able to formally analyze only two components of the variance in R&D costs-those associated with therapeutic class and year of introduction. It is possible that other factors contribute to a positive relationship between R&D costs and sales. This is an important issue for further research. However, it seems clear from the analysis that sales are much more skewed than R&D costs. Deciles While many of these lower decile products will be contributors to firm profits (in the sense that incremental expected cash flows exceed incremental development and capital investment cost), a firm's fully allocated R&D costs must also be covered over the long run. In this regard, the results indicate that a firm must have an occasional "blockbuster" compound from the top deciles of the sales distribution, if it is to cover the large fixed costs which characterizes the drug development process.
D. The Effect of Changing Prices on Present Va/ties
In this section, our analytical framework is utilized to examine how present values have been affected by the real pharmaceutical price increases that have occurred since 1980. To accomplish this objective, present values are calculated under the hypothetical assumption that contribution margins would have remained constant at their minimum value of the late 1970s. In our analysis, this is tantamount to the assumption that drug prices since 1980 rose only at the rate of inflation (i.e., no real price increases), rather than experiencing net price increases over this period. 26 The results are reported in the lower half of Table 1 . They clearly demonstrate that there is a rather dramatic effsect on the computed present values. For the 1970 to 1979 sample, there is a decline of 13.7 million dollars or a 16 percentage point decline from 25 It is also important to note in this regard that eight of the ten drugs which make up the top decile during the 1970s come from the 1975 to 1979 sub-period. Hence, a large factor in the observed upward shift in the economic performance of NCE introductions was the increased number of "blockbuster" products introduced in the latter part of the 1 970s. 26 In this regard, real price increases were found to explain over 87 percent of the variance in pre-tax margins over the period 1973 to 1985. See the discussion of this point in footnote 19. the baseline value. The impact is even larger for the 1975-79 cohort where the percentage decline is over 18 percent.
These changes are significant in light of the fact that the average compound's present value under the constant margin scenario is considerably less than average R&D investment cost. The analysis therefore indicates that without the real price increases which have occurred since 1980, and holding all other factors the same, the drug industry would not have recovered total allocated costs from their portfolio of 1970s drug introductions. The rapid rate of growth in industry R&D expenditures, that has occurred since the late 1970s, undoubtedly would also have been adversely affected if real prices had remained constant.
Sensitivity of Results to Changes in Various Assumptions
The analysis of our basic case, presented in Table 1 , necessarily embodies a number of assumptions about various parameters and future economic conditions. In this section we examine the consequences of alternative assumptions concerning these parameters.
A. Pre-tax Margins in Future Years
An alternative scenario to our baseline assumption of stable margins for future periods is declining margins in the 1990s. As discussed above, the case for declining margins over time stems from the likelihood of growing cost containment pressures here and abroad.27 Under this case, margins are projected to decline, beginning in 1990, from 40 percent to a steady state value of 36 percent. The latter value is representative of the mean experience for our sample of observed values (Figure 3) .
The opposite scenario, increasing contribution margins over future periods, is also examined. This could occur if U.S. drug prices in the 1 990s were to outpace inflation by an amount sufficiently large enough to dominate the effect of declining real prices abroad. We view this as very unlikely for the reasons cited. Nevertheless, the case of increasing margins is considered in order to see how sensitive the results are to this scenario. Specifically, for this case, it is assumed that contribution margins will steadily rise through the early 1990s, until they reach a steady state value of 44 percent.
The results for these alternative scenarios are presented in the first two rows of Table  2 . We focus on the 1970 to 1979 cohort in these sensitivity analyses. There is not a large impact on the estimated present values for either the increasing or declining margin cases. The new values are within a few percent of previous estimates. This is perhaps surprising, but it reflects the fact that the changes in assumptions about future contribution margins affect only the later years of the life cycle for our sample, and these years are also heavily discounted in economic terms. There would be much greater effects, of course, for new product introductions just beginning their market life at the present time.
B. Greater Generic Conmpetition and Shorter Product Life
Our basic case embodies assumptions on sales erosion of the pioneer brands to generic competitors that are consistent with current experience. However, there appears to be a strong dynamic trend toward intensifying generic competition. The next decade is likely to witness significantly greater market penetration of generic drugs, consistent with the evolution of cost containment programs in both the public and private sectors. There is currently a strong movement toward increased generic drug usage by HMOs and other managed health care institutions.
In order to test the sensitivity of our results to the prospects of increased generic competition, a scenario was examined in which pioneer sales erode faster over time and 27 Drug prices in recent years have lagged inflation for established drug therapies in all major markets outside the United States. These same cost containment pressures are likely to be increasingly felt in the U.S. market in coming periods. lose 80 percent of the total market to generics within six years after patent expiration. This is in contrast to the base case which assumes an equilibrium share for generics of 60 percent after five years. Under the increased generic competition scenario, we also assume a shortened product life of 20 years, reflecting the lower sales values associated with the back end of the product life cycle curve.
The results are presented in the third row of Table 2 . Increased generic competition and shorter product life reduce the present value of returns in the basic cohort by approximately 9 percent. A breakeven also does not occur within the assumed commercial life for the average drug product.
The same cost containment pressures that are likely to increase generic usage will also probably operate to constrain future prices and margins in future periods. Hence it is useful to consider the case of declining margins and increased generic usage in combination. This case is considered in the fourth row of Table 2 . The results show that these factors are largely additive in nature. The present value of cash flows in this case are reduced by over 10 percent below the base case and the gap between returns and R&D costs is further widened. Once again, the impact of these factors is moderated by the fact that they occur relatively late in the product life cycle here and are significantly discounted for 1 970s introductions. If cost containment measures affect future introductions earlier in the life cycle, their impact will be substantially increased.
C. R&D Investment
The next sensitivity analysis involves R&D investment expenditures. The baseline utilized a pre-tax average R&D investment of 125 million dollars for 1 970s introductions. This translates into an after tax value of 81 million dollars given the assumed 35 percent tax rate. However there is considerable variability around this average value. Our analysis of year to year fluctuations during the 1970s suggest a plus or minus 20 percent bound would be a plausible range for a sensitivity analysis on this parameter.
In Table 2 , rows 5 and 6, results are presented assuming these alternative values for R&D investment. As one might expect, our findings are quite sensitive to the R&D investment variable. An increase of 20 percent in the present value of R&D outlays creates a significant shortfall between the after tax cash flows and R&D investment. The average introduction fails to achieve breakeven on a discounted payback basis. On the other hand, a decrease of 20 percent from baseline values has the opposite effect. In particular, the average introduction would then earn almost 20 million dollars and achieve breakeven discounted payback in year 16 of market life. This is 7 years sooner than in the baseline case.
These results point up the importance of upfront R&D investment to economic performance and breakeven lifetimes. Since FDA regulations and review times are one of the primary factors influencing R&D investment outlays, this also highlights the important effect that regulatory developments can have on the returns to pharmaceutical R&D. This is also a principal finding of an earlier study on breakeven lifetimes (Grabowski and Vernon 1982).28
D. Foreign Sales Multiplier
The next sensitivity analysis presented in Table 2 concerns the foreign sales multiplier. Worldwide sales were set in the baseline analysis at 1.9 times domestic sales based on an analysis of individual product as well as balance sheet data. Since these values involve the high and low ends of the spectrum, our results do not appear highly sensitive to this parameter.
E. Effective Tax Rate
The final two rows of Table 2 show the sensitivity of the results to alternative tax rate assumptions. A representative tax rate of 35 percent is utilized in our base case. Table 2 shows the effect of alternatively assuming tax rates of 30 and 40 percent over the full market life of each NCE introduction. The average present value of returns would be decreased by 9.3 percent if a tax rate of 40 percent is employed. At the same time, however, the present value of the mean R&D investment would decrease by a comparable amount of 7.7 percent, given that R&D costs are tax deductible. Consequently, breakeven lifetimes change only marginally from the baseline case and overall, our results are little affected by tax rates changes of this magnitude.
F. Overview
In general, the results in Table 2 show our findings are quite robust to changes of various parameters within a plausible range around the baseline values.29 The most sensitive factor is R&D investment outlays. Given this result, further analyses of pharmaceutical R&D costs and how these costs have been changing over time would appear to be a high priority for future work.30 Another factor to which returns were sensitive was 28 In our earlier paper, we found that one year reduction in upfront regulatory review time will result in three or more years reduction in the breakeven lifetime (Grabowski and Vernon 1982). 29 In addition to the sensitivity analyses reported in Table 2 , we also considered alternative scenarios for other parameters such as the required investment in physical capital for a typical new drug. The findings of the baseline case were robust to plausible variations in this and other factors. 30 The 125 million dollar R&D cost figure for this study is based on the mid-1970's, corresponding to our sample of the 1970's introductions. Given the continuing upward trend in real R&D costs observed here, the mean R&D cost of a new drug introduction at the present time should be substantially higher than this value. Preliminary results from a new study of R&D costs by Hansen et al. ( 1989) suggest this is the case. the industry's ability to achieve price increases, especially in the first several years after product launch. This is highlighted by our findings on the effect of changes in the product margins in Table 1 .
Summary and Conclusions
A major finding of this study is that new drug product introductions in the 1970s realized returns in line with the 9 percent industry cost of capital. Our finding in this regard represents a departure from prior work which has generally found lower returns to pharmaceutical R&D, both in absolute terms and relative to the industry's cost of capital. One explanation for this difference in findings is that our study considers a more recent sample of NCE introductions and utilizes time trends on sales and cost data through the mid 1980s.
Another important finding is that the economic performance of new drugs introduced during the latter half of the 1970s was markedly better than that of the early 1970s introductions. In this regard, eight of the ten drugs in the top decile of sales during the 1970s represented introductions which occurred after 1974. This fact suggests a possible improving situation in terms of technological opportunities in the pharmaceutical industry which become manifest in the latter half of the 1970s. This hypothesis is consistent with the behavior of industry R&D expenditures. The industry's growth in real R&D expenditures has been on the order of 10 percent since 1977, more than double the growth rate of the prior decade. Very preliminary research also suggests that the new drugs introduced during the 1980s experienced sales patterns in their early years of market life that are consistent with the strong economic performance of the late 1970s introductions.3'
In comparison to past work, our study considers the effects of a number of significant economic changes that have occurred in the pharmaceutical industry over the past decade. Specifically, our analysis indicates that higher real drug prices in the 1980s had an especially important effect in allowing firms to cover R&D investments. A sensitivity analysis performed in the paper indicated that, if no real price increases had occurred, and drug contribution margins correspondingly remained at their minimum values of the late 1970s, the present value of returns would have been reduced by 16 percent for the average 1970s new drug introduction. Under this scenario, and holding other factors constant, the typical new drug introduction would not have been able to cover average R&D costs.
Our sensitivity analysis also considered the effects of evolving cost containment pressures in the pharmaceutical industry. These pressures are likely to result in a greater degree of generic competition, shorter product lives and lower margins than assumed in our baseline case estimates. If these factors become increasingly significant during the 1990s, they would have a negative effect on the returns earned by past introductions. This effect would be moderated by the fact that these events would affect only the later years of market life. However, these changes would have a much larger impact on future new drug candidates. A prospective analysis of the effects of evolving policy changes on future introductions is an important task for further study. 31 Average sales for new drug introductions during the 1980s are generally equal to or higher than those observed at comparable points in the life cycle of 1970s introductions. At the same time, mean R&D costs would also be expected to be greater for these 1980s introductions. 
